Blood Cancer Breakthrough: Patient Achieves Complete Response After Just 2 Doses of Novel Cell Therapy New data shows complete molecular remission in blood cancer patient using innovative gamma delta T cell therapy. Treatment success achieved in just two weeks. See results.

#TCBP TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

www.stocktitan.net/news/TCBP/tc-bio-pharm-a...

TC BioPharm Faces Nasdaq Exit: What This OTC Markets Move Means for Investors TC BioPharm transitions to OTC Markets after Nasdaq delisting, while maintaining SEC reporting and continuing gamma-delta T cell therapy development for cancer treatment.

#TCBP TCBP Announces Transition from Nasdaq to OTC Markets

www.stocktitan.net/news/TCBP/tcbp-announces...

TC BioPharm Slashes Annual Costs by $4.2M with Major Strategic Overhaul TC BioPharm transitions to CDMO model, reducing operational costs by 55%. Strategic restructuring yields $4.2M annual savings while positioning for clinical trial expansion.

#TCBP TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

www.stocktitan.net/news/TCBP/tcbp-announces...

$TCBP ready to pop IMO. I hold a couple of thousand. Making solid moves strategically and has a relatively high short position with a small float. #TCBP #Investing

Will This Ophthalmic Acquisition Transform TC BioPharm's $8 Billion Market Potential? TCBP signs non-binding LOI to acquire company with FDA-approved glaucoma treatment, targeting $8B+ market with revenue expected in 2025. Deal closing anticipated Q3 2025.

#TCBP TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

www.stocktitan.net/news/TCBP/tcbp-announces...

Clinical Trial Success: TC BioPharm's Leukemia Treatment Shows Zero Adverse Events TC BioPharm completes Cohort A in ACHIEVE trial for AML treatment, demonstrating promising safety profile and disease stabilization in multiple patients.

#TCBP TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

www.stocktitan.net/news/TCBP/tcbp-announces...

JUST IN: ( NASDAQ: #TCBP ) InvestorNewsBreaks - TC BioPharm Holdings PLC (NASDAQ: TCBP) Advances ACHIEVE Trial With Completion of First Cohort B Dosing

News; ( NASDAQ: #TCBP ) TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP Clinical Trial Breakthrough: Zero Adverse Events as AML Treatment Shows Promise TC BioPharm reports successful completion of initial Cohort B dosing in ACHIEVE trial, with promising safety data and no adverse events in AML treatment.

#TCBP TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

www.stocktitan.net/news/TCBP/tcbp-announces...

TC BioPharm's Major ADS Restructure: What This 1:20 Ratio Change Means For Your Holdings TC BioPharm implements significant ADS ratio adjustment, moving from 1:200 to 1:4000 ordinary shares. Exchange process managed by Bank of New York Mellon with fractional shares to be sold.

#TCBP TCBP to Implement ADS Ratio Change

www.stocktitan.net/news/TCBP/tcbp-to-implem...

TC BioPharm Advances Novel Bird Flu Treatment TCB008 Following First US H5N1 Death TC BioPharm initiates preclinical studies for TCB008, targeting H5N1 bird flu treatment. Company seeks university partnerships to accelerate development amid growing concerns.

#TCBP TCBP Announces H5N1 Proof of Concept Studies Intention

www.stocktitan.net/news/TCBP/tcbp-announces...

#SXTP #TCBP #ZVSA #BCAN

LETS GET IT!

#Stocks #StockMarket #Invest

TC BioPharm Maintains Strong Nasdaq Presence as Cancer Therapy Developer Continues Trading TC BioPharm secures continuous trading of its ADSs on Nasdaq Global Select Market, reinforcing its position in gamma-delta T cell cancer therapy development.

#TCBP TCBP Trading Continues Unabated on Nasdaq Stock Exchange

www.stocktitan.net/news/TCBP/tcbp-trading-c...

#TCBP TC Biopharm Announced It Has Advanced Negotiations With Both Of Its Previously Aforementioned #Acquisition Candidates. The Company Will Be Focusing Its Acquisition Efforts On Two Main Areas; Natural Kill Cell #Technologies And CAR-Related Technologies

$TCBP Dec 31, 2024

TC BioPharm Advances Strategic Acquisitions in NK Cell and CAR Technologies for Cancer Treatment Expansion TC BioPharm progresses M&A talks targeting NK cell and CAR technologies to expand therapeutic reach into autoimmune diseases and solid tumors, enhancing TCB008 platform capabilities.

#TCBP TCBP Provides Update on Acquisition Strategy and Current Targets

www.stocktitan.net/news/TCBP/tcbp-provides-...

MY TOP THREE CHOICES RIGHT NOW
#TCBP #ME AND #QNTM. Follow me at X.COM, as all posts go there first before here.

#Stocks

TC BioPharm Reports Strong Safety Data in Phase 2b AML Trial, Zero Drug-Related Adverse Events TC BioPharm's ACHIEVE trial shows promising safety profile for TCB008 in AML treatment, with multiple patients completing full dosing regimen. Key enrollment milestones reached.

#TCBP TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients

www.stocktitan.net/news/TCBP/tcbp-advances-...

IM SHARING MY LATEST INFO ABOUT $TCBP It appears my firm I'm under contract is buying more shares tomorrow. In fact, I just got a bonus on top of my commission fees.

#Bitcoin #StocksToBuy #TCBP #stocksinnews

My team and I have been tirelessly working to identify the right stocks, and it seems we've reached a consensus. We've acquired 700,000 shares of $TCBP. With its dividend proposal and current share price, we couldn't let this opportunity slip by.

#TCBP #StocksToWatch #DividendStocks

BREAKING NEWS: ( NASDAQ: #TCBP ) InvestorNewsBreaks - TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Special Dividend for Shareholders Amid Ongoing Support

#StockMarket #News

JUST IN: ( NASDAQ: #TCBP ) TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

#StockMarket #News

TC BioPharm Reports Positive Safety Data in ACHIEVE Trial, Plans Dose Expansion for Cancer Cell Therapy | TCBP Stock News TC BioPharm's gamma-delta T cell therapy shows promising safety profile in cancer trial. Company advances treatment protocol with dose escalation and site expansion planned.

#TCBP TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial

#clinicaltrial #StockMarket #stocks

www.stocktitan.net/news/TCBP/tcbp-provides-...

Just In: ( NASDAQ: #TCBP ) TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex Grant

#StockMarket #News

News; ( NASDAQ: #TCBP ) Shares of This Biotech Surge Following Collaboration Announcement For Monkeypox Research

#StockMarket #News

JUST IN: ( NASDAQ: #TCBP ) InvestorNewsBreaks - TC BioPharm Holdings PLC (NASDAQ: TCBP) Announces Collaboration for Monkeypox Treatment Development

#StockMarket #News

JUST IN: ( NASDAQ: #TCBP ) TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #TCBP ) InvestorNewsBreaks - TC BioPharm Holdings PLC (NASDAQ: TCBP), Carnegie Mellon University Partner to Potentially Revolutionize Donor Selection, Matching Processes with AI

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #TCBP ) TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening

#StockMarket #News

Just In: ( NASDAQ: #TCBP ) TCBP Announces Site Opening of Guys and St. Thomas Hospital

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #TCBP ) InvestorNewsBreaks - TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Completes ACHIEVE Trial Full-Dose Regimen for First Patient

#StockMarket #News